<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04735666</url>
  </required_header>
  <id_info>
    <org_study_id>1.1</org_study_id>
    <nct_id>NCT04735666</nct_id>
  </id_info>
  <brief_title>European TauroPace Registry - an University Hospital Schleswig-Holstein Prospective Observational Clinical Study</brief_title>
  <acronym>ETPR</acronym>
  <official_title>European TauroPace Registry - an University Hospital Schleswig-Holstein Prospective Observational Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      University Hospital Schleswig-Holstein Campus Kiel is sponsoring the European TauroPace&#xD;
      Registry, a prospective, multi-centre, international clinical cohort study. This study will&#xD;
      evaluate the ability of TauroPace™ CIED irrigation solution to reduce major Cardiac&#xD;
      Implantable Electronic Device (CIED) infections in the first three months after any CIED&#xD;
      related surgery procedure (following any CIED generator replacement, upgrade, downgrade&#xD;
      revision, or de novo implant).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After retrieval of Patient Informed Consent (PIC) from eligible patients, patients will&#xD;
      undergo any CIED-related surgery procedure in any CIED with TauroPace™. Follow-up will be at&#xD;
      1 and 3 months. Endpoints are CIED infection, adverse events and incidents.&#xD;
&#xD;
      Participants will be trained to be aware of the clinical criteria for CIED infection as&#xD;
      defined in 5.4. of the current study protocol. Participants will be told to call whenever the&#xD;
      slightest signs of the mentioned criteria are observed or in any case of unusual or suspect&#xD;
      indisposition. If the call gives indication for CIED infection, adverse events or incidents&#xD;
      the participant calling will be examined in the ward by a cardiologist or cardiac surgeon&#xD;
      with expertise in rhythm surgery. Decision on presence of CIED infection, adverse event or&#xD;
      other incident will be made according to the respective examination results and the clinical&#xD;
      criteria defined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>CIED infections</measure>
    <time_frame>three months</time_frame>
    <description>CIED infections occurring in an observation period after any CIED related surgery in different CIED using a regimen with surface disinfection of CIEDs.</description>
  </primary_outcome>
  <enrollment type="Anticipated">2300</enrollment>
  <condition>CIED Related Infection</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TauroPace™</intervention_name>
    <description>TauroPace™ is intended to be used as a disinfecting solution during any CIED related surgery procedure or handling of any uncoated or silicon-, epoxy- or polyurethane-coated CIED (including its components, e.g., leads) made of titan or stainless steel in any adult patient requiring or carrying a CIED.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consist of every subsequent participant eligible for any CIED related&#xD;
        surgery with TauroPace™&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Use of TauroPace™ is indicated and not contra-indicated according to its current&#xD;
             Instructions For Use (IFU)&#xD;
&#xD;
          -  Participant is eligible for a CIED related surgery procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&lt;18years&#xD;
&#xD;
          -  Participant incapable of signing Patient Informed Consent (mentally or physically) or&#xD;
             does not sign.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik Bonnemeier, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital SH Campus Kiel Department of Cardiology Director Electrophysiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinician scientist, MD</last_name>
    <phone>+11-49-17696450666</phone>
    <email>sportmedic@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jana Henke</last_name>
    <email>henke.jana@gmx.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Krankenhaus Landshut Achdorf</name>
      <address>
        <city>Landshut</city>
        <state>Bavaria</state>
        <zip>84036</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Borov, MD</last_name>
      <phone>00498714042192</phone>
      <email>stefan.borov@lakumed.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Borov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Henke</last_name>
      <email>henke.jana@gmx.de</email>
    </contact>
    <contact_backup>
      <last_name>Clinician scientist, MD</last_name>
      <email>sportmedic@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hendrik Bonnemeier, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Great Western Hospital</name>
      <address>
        <city>Swindon</city>
        <state>Wiltshire</state>
        <zip>SN3 6BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Foley, MD</last_name>
      <phone>+44 7973 646214</phone>
      <email>p.foley1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Paul Foley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>participant data is recorded in a pseudonymous manner in the centre, before statistical analysis data is anonymized</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

